Cervical Cancer Education
Cervical cancer treatment is being transformed by antibody-drug conjugates, checkpoint inhibitor combinations, and evolving approaches to persistent/recurrent disease. Knowledge Med sessions help physicians navigate these advances through interactive case simulations led by gynecologic oncology faculty.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing cervical cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Integrating pembrolizumab with chemotherapy-bevacizumab in first-line metastatic disease
- Selecting patients for tisotumab vedotin (Tivdak) in recurrent cervical cancer
- Managing persistent disease after chemoradiation
- Applying PD-L1 and other biomarkers to guide treatment decisions
What Sessions Cover
Knowledge Med Cervical Cancer sessions use interactive case simulations to address these topics and more.
- First-line immunotherapy-chemotherapy-bevacizumab in advanced cervical cancer
- Antibody-drug conjugates in recurrent cervical cancer: tisotumab vedotin and beyond
- Pembrolizumab maintenance after chemoradiation: patient selection and monitoring
- Emerging targets and clinical trial landscape in cervical cancer
Interactive Cervical Cancer Sessions
Case Simulations
Work through realistic cervical cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key Cervical Cancer clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a Cervical Cancer Session
Third-party, non-promotional cervical cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session